The Latin America, Middle East and Africa Opioid Use Disorder (OUD) Market should witness market growth of 13.0% CAGR during the forecast period (2023-2030).
Medicare and all state Medicaid programs cover the treatment services offered by opioid treatment programs (OTPs). State Medicaid programs frequently pay for OTP services in daily or weekly bundles that include methadone doses, toxicological testing, nurse services, and counselling, using the code H0020. About 40% of all non-elderly people with opioid use disorder (OUD) are covered by Medicaid. The opioid use disorder market is expected to grow as a result of these treatment initiatives.
The Middle East and North Africa (MENA) are severely affected by the global public health problem known as opioid use disorder (OUD). As many as 12 Arab nations have shown significant opioid use rates, with Bahrain and Kuwait showing particularly high rates. The government and culture both have an impact on the complex opioid use in the ME. Opioid consumption is lower in oil-rich countries like Kuwait, Bahrain, Saudi Arabia, the United Arab Emirates, and Qatar. Iran stands out for having a high opioid usage rate.
The 'opioid crisis'that other parts of the regional are going through could make Latin American countries' inadequate pain treatment worse. Regulating organizations in the area have already expressed alarm about it. To create a position paper on appropriate opioid usage in chronic pain, the Latin American Federation of IASP Chapters (FEDELAT) gathered a team of regional experts in So Paulo, Brazil. The group's research of the needs and unique characteristics of the area forms the basis for all recommendations. These advancements may help to improve laws and pain treatment, as well as to stop the abuse and misuse of these drugs. All these elements are estimated ort support the growth of the regional market.
The Brazil market dominated the LAMEA Opioid Use Disorder (OUD) Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $114.4 million by 2030. The Argentina market is anticipated to grow at a CAGR of 13.6% during (2023-2030). Additionally, The UAE market would exhibit a CAGR of 12.7% during (2023-2030).
Based on Drug Class, the market is segmented into Buprenorphine, Methadone and Naltrexone. Based on Route of Administration, the market is segmented into Parenteral and Oral. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies & Stores and Online Pharmacies. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Indivior PLC (Reckitt Benckiser Group plc), Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, Inc.), Orexo AB (Orexo US, Inc.), Alkermes PLC, Titan Pharmaceuticals, Inc., Camurus AB, AstraZeneca PLC, Hikma Pharmaceuticals PLC, Mallinckrodt PLC , and Viatris, Inc.
Medicare and all state Medicaid programs cover the treatment services offered by opioid treatment programs (OTPs). State Medicaid programs frequently pay for OTP services in daily or weekly bundles that include methadone doses, toxicological testing, nurse services, and counselling, using the code H0020. About 40% of all non-elderly people with opioid use disorder (OUD) are covered by Medicaid. The opioid use disorder market is expected to grow as a result of these treatment initiatives.
The Middle East and North Africa (MENA) are severely affected by the global public health problem known as opioid use disorder (OUD). As many as 12 Arab nations have shown significant opioid use rates, with Bahrain and Kuwait showing particularly high rates. The government and culture both have an impact on the complex opioid use in the ME. Opioid consumption is lower in oil-rich countries like Kuwait, Bahrain, Saudi Arabia, the United Arab Emirates, and Qatar. Iran stands out for having a high opioid usage rate.
The 'opioid crisis'that other parts of the regional are going through could make Latin American countries' inadequate pain treatment worse. Regulating organizations in the area have already expressed alarm about it. To create a position paper on appropriate opioid usage in chronic pain, the Latin American Federation of IASP Chapters (FEDELAT) gathered a team of regional experts in So Paulo, Brazil. The group's research of the needs and unique characteristics of the area forms the basis for all recommendations. These advancements may help to improve laws and pain treatment, as well as to stop the abuse and misuse of these drugs. All these elements are estimated ort support the growth of the regional market.
The Brazil market dominated the LAMEA Opioid Use Disorder (OUD) Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $114.4 million by 2030. The Argentina market is anticipated to grow at a CAGR of 13.6% during (2023-2030). Additionally, The UAE market would exhibit a CAGR of 12.7% during (2023-2030).
Based on Drug Class, the market is segmented into Buprenorphine, Methadone and Naltrexone. Based on Route of Administration, the market is segmented into Parenteral and Oral. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies & Stores and Online Pharmacies. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Indivior PLC (Reckitt Benckiser Group plc), Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, Inc.), Orexo AB (Orexo US, Inc.), Alkermes PLC, Titan Pharmaceuticals, Inc., Camurus AB, AstraZeneca PLC, Hikma Pharmaceuticals PLC, Mallinckrodt PLC , and Viatris, Inc.
Scope of the Study
By Drug Class
- Buprenorphine
- Methadone
- Naltrexone
By Route of Administration
- Parenteral
- Oral
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Stores
- Online Pharmacies
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Indivior PLC (Reckitt Benckiser Group plc)
- Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, Inc.)
- Orexo AB (Orexo US, Inc.)
- Alkermes PLC
- Titan Pharmaceuticals, Inc.
- Camurus AB
- AstraZeneca PLC
- Hikma Pharmaceuticals PLC
- Mallinckrodt PLC
- Viatris, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 4. LAMEA Opioid Use Disorder (OUD) Market by Drug Class
Chapter 5. LAMEA Opioid Use Disorder (OUD) Market by Route of Administration
Chapter 6. LAMEA Opioid Use Disorder (OUD) Market by Distribution Channel
Chapter 7. LAMEA Opioid Use Disorder (OUD) Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Indivior PLC (Reckitt Benckiser Group plc)
- Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, Inc.)
- Orexo AB (Orexo US, Inc.)
- Alkermes PLC
- Titan Pharmaceuticals, Inc.
- Camurus AB
- AstraZeneca PLC
- Hikma Pharmaceuticals PLC
- Mallinckrodt PLC
- Viatris, Inc.
Methodology
LOADING...
